Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to seribantumab for the tumor-agnostic treatment of advanced solid tumors that harbor NRG1 gene fusions. Seribantumab is currently being evaluated in the ongoing Phase 2 CRESTONE study, for which initial data will be presented in an oral presentation at the upcoming American Society of Clinical Oncology (ASCO) 2022 Annual Meeting on Tuesday, June 7, 2022.
https://finance.yahoo.com/news/elevation-oncology-announces-fda-fast-113000618.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.